Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixabepilone and SBRT in Triple Negative Metastatic Breast Cancer
NCT01818999Phase 2Withdrawn
- Sponsor
- UT Southwestern Medical Center
- Start
- Aug 2013
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixabepilone in triple-negative breast cancer (TNBC), sponsored by UT Southwestern Medical Center. Primary endpoint: Median Progression Free Survival at 5 years. Planned start Aug 2013; status: withdrawn.
02
Drugs
ixabepilone
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01818999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01818999.